Pandemic & Infectious Disease — 2026-08-26
Mpox is resurging in new countries with children disproportionately affected, while the DRC Ebola outbreak reaches record scale. The FDA has approved Moderna's mRNA-based influenza vaccine mFLUSIVA for adults 50 and older, marking a significant expansion of mRNA technology into seasonal flu prevention.
Pandemic & Infectious Disease — 2026-08-26
Active Outbreak Tracker
Mpox — Global / Multiple Countries
- Status: Active transmission in new countries
- Key Development: Mpox has re-emerged in new countries, with children appearing particularly affected in the current outbreak. The previous public health emergencies in 2022 and 2024 saw the virus reported in 145 countries, but the current resurgence shows a concerning shift toward pediatric vulnerability.
- Response: Public health authorities are assessing containment strategies, with attention focused on protecting children in affected regions.
Ebola (Bundibugyo) — DRC / Uganda
- Status: Record-scale outbreak ongoing
- Key Development: The DRC Ebola outbreak has reached record scale, according to the latest biodefense briefing. The outbreak, caused by the Bundibugyo ebolavirus species, continues to challenge response efforts in the region amid ongoing vaccine trial discussions.
- Response: International health agencies and biodefense authorities are monitoring the outbreak's trajectory and coordinating response measures.
Vaccine & Treatment Pipeline
- mFLUSIVA (mRNA-1010) (Moderna): The FDA has approved mFLUSIVA (mRNA-101
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
